Baseline predictions of PACC progression trajectories in preclinical AD improve the precision and power of treatment effect assessments
Baseline tau PET was the strongest predictor of PACC decline. Using baseline-predicted PACC decline as APC can enhance treatment effect estimates and trial efficiency in preclinical AD.
Authors
- Michael Donohue (ORCID: https://orcid.org/0000-0001-6026-2238)
- Shobha Dhadda (ORCID: https://orcid.org/0000-0002-7290-7168)
- K. N. Johnson
- Yuanqing Ye (ORCID: https://orcid.org/0000-0001-5708-8961)
- REMA RAMAN (ORCID: https://orcid.org/0000-0002-4096-6390)
- Lynn D. Kramer
- Paul S. Aisen
- Michael C. Irizarry
- Viswanath Devanarayan
- Reisa A. Sperling
Institutions
- University of Southern California (US)
- Brigham and Women's Hospital (US)
- Autism Research Institute (US)
- Harvard University (US)
- University of Illinois Chicago (US)
- Massachusetts General Hospital (US)
- Eisai (United States) (US)
- Southern States University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_099560
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00